Hong Kong-listed Everest Medicines Limited is mulling tweaking its business strategy of in-licensing Asia territory rights to foreign drug candidates, with a potential focus on renal diseases taking the front seat.
The Chinese biotech’s tentative departure from the crowded therapeutic area of oncology surfaced after it sold back to Gilead Sciences, Inc./Immunomedics, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?